The present study, together with our previous findings in prostate cancer (Di Donato et al., 2018, 2019), further points to the relevance of NGF signaling in “gender-related cancers” and paves the way for new therapeutic opportunities in the clinical management of TNBC patients, who often exhibit or develop drug resistance. The gene discussed is NGF; the disease is prostate cancer.